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Abstract A transfectant HeLa cell clone expressing HFE under
the control of a tetracycline-repressible promoter was generated.
HFE expression was fully repressed by the presence of
doxycycline, while it was strongly induced by growth in the
absence of doxycycline. HFE accumulation was accompanied by
a large (V10-fold) decrease in H- and L-ferritin levels, by a
V3^4-fold increase in transferrin receptor, and a V2-fold
increase in iron regulatory protein activity. These indices of
cellular iron deficiency were reversed by iron supplementation
complexes. The overexpressed HFE immunoprecipitated to-
gether with transferrin receptor, indicating a physical association
which is the likely cause for the observed V30% decrease in
55Fe-transferrin incorporation after 18 h incubation. In the HFE-
expressing cells the reduction in transferrin-mediated iron
incorporation was partially compensated by a V30% increase
in non-transferrin iron incorporation from 55Fe-NTA, evident
after prolonged, 18 h, incubations. The findings indicate that
HFE binding to transferrin receptor reduces cellular iron
availability and regulates the balance between transferrin-
mediated and non-transferrin-mediated cellular iron incorpora-
tion.
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1. Introduction
Hereditary hemochromatosis (HHC) is a common autoso-
mal recessive disorder characterized by an upregulated iron
absorption [1]. The hemochromatosis gene encodes the HFE
protein (formerly HLA-H) resembling major histocompatibil-
ity complex class I molecules [2]. The HFE Cys282CTyr
mutation, which is homozygous in s 70% of HHC patients
[3^5], results in the loss of a structural disul¢de bond, prevents
association with L2-microglobulin (L2m) and proper presenta-
tion to cell surfaces [6,7]. Mice deleted for the HFE or the
L2m gene show a fast accumulation of iron in the parenchyma
cells of liver similar to that observed in HHC [8,9]. The arti-
¢cially induced C282Y mutation in mice produces an HHC-
like phenotype less severe than that of HFE null mice [10].
HFE mRNA is expressed in various tissues with the highest
levels in liver and intestine [2], and immunohistochemical
HFE was found in the syncytiotrophoblasts of human placen-
ta [11], in the epithelial cells of the alimentary tract, in the
crypt cells of the small intestine [12] and in Kup¡er cells, in
liver and brain sinusoidal cells, and in scattered epithelial cells
in the crypts of the small and large intestine [13].
HFE associates with the transferrin receptor (TfR) more
tightly at neutral (pH 7.5) than at acidic pH (pH 6) and the
binding reduces TfR a⁄nity for Fe-transferrin [14,15]. In
transfected cells an association between HFE and TfR occurs
in the endoplasmic reticulum/cis-Golgi compartment soon
after synthesis, it stabilizes HFE protein from degradation
[16], and reduces cellular iron uptake [17,18]. HeLa cell clones
overexpressing HFE showed low levels of endogenous ferritins
and a reduced capacity to incorporate 55Fe-transferrin, while
they took up 55Fe-NTA at the same rate as control clones
[17]. The pH-dependent association with TfR appears a major
and important linkage of HFE with cellular iron metabolism,
but its physiological role in the regulation of body iron ab-
sorption and tissue distribution is unclear.
We describe the production of a HeLa cell clone expressing
HFE under the control of a tetracycline-inducible promoter.
Analysis of the clone showed that HFE overexpression is
accompanied by a large (V10-fold) decrease of H- and
L-ferritin accumulation, by a V3^4-fold increase in TfR pro-
tein and by a strong activation of iron responsive element
(IRE) binding activity of the iron regulatory proteins (IRPs)
which are the typical indices of cellular iron de¢ciency. The
cells have a reduced capacity to incorporate 55Fe-transferrin,
while they have an increased capacity to accumulate non-
transferrin 55Fe-NTA.
2. Materials and methods
2.1. DNA, expression and puri¢cation of HFE protein
Full length human HFE cDNA was generated by RT-PCR from
mRNA extracted from human pulmonary cells. The cDNA was sub-
cloned into pCDNA3.1 vector (Invitrogen) and pUDH10-3 vector
(Clontech) fused to the myc-tag peptide at the C-terminus. The
cDNA sequence encoding HFE ectodomains (residues 26^304) was
subcloned into vector pET12b for expression in Escherichia coli, fused
to a polyhistidine tag. DNA sequencing con¢rmed that the plasmids
encoded the correct protein sequence reported in [2]. Transformation
of E. coli strain BL21(DE3)pLysS and protein expression were per-
formed essentially as described [19]. HFE was puri¢ed by a⁄nity
chromatography on Ni-NTA Sepharose, and protein puri¢cation
was con¢rmed by SDS-PAGE and Coomassie blue staining. Protein
concentration was determined with the BCA assay (Pierce) calibrated
on bovine serum albumin.
2.2. Antibodies, metabolic labeling and SDS-PAGE
Mouse anti-HFE antibodies were elicited by the puri¢ed and dena-
tured recombinant HFE protein from E. coli. Antibody speci¢city was
assessed by Western blotting and immunoprecipitation. To increase
antibody production we induced antibody-containing ascitic £uid in
some mice by intraperitoneal injection of pristane [20]. Anti-myc-tag
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antibody 9E10 was purchased from Sigma and anti-transferrin recep-
tor antibody from Zimed, anti-ferritin H- and L-chain monoclonal
antibodies and ELISA assays for H- and L-ferritins calibrated with
recombinant H- and L-ferritin homopolymers are described in [21].
Metabolic labeling with [35S]methionine, immunoprecipitations, SDS-
PAGE and £uorography were performed as described in [19]. Immu-
nocytochemistry was performed on ¢xed cells permeabilized with
0.5% Triton X-100 using anti-myc-tag antibody (2 Wg/ml) followed
by TRITC anti-mouse IgG rabbit antibodies (Dako) and the stain
visualized by £uorescence microscopy.
2.3. Cell culture
HeLa-Tet-O¡ cells (Clontech) were co-transfected with plasmid
pUDH10-3-HFE and with plasmid pTK-Hyg (Clontech) using the
calcium phosphate method [19]. The colonies selected with hygro-
mycin D (150 Wg/ml) and doxycycline (2 Wg/ml) were screened for
the HFE gene by PCR and for HFE expression by immunoprecipita-
tion of metabolically labeled cells with anti-myc antibody 9E10. The
selected cells were maintained in Dulbecco’s modi¢ed Eagle’s medium
(DMEM, Gibco) supplemented with 10% fetal bovine serum (Clon-
tech), 100 Wg/ml G418 (Geneticin, Sigma), 150 Wg/ml hygromycin D
(Clontech) 100 U/ml penicillin, 100 Wg/ml streptomycin, 1 mM L-glu-
tamine and with (Dox+) or without (Dox3) 2 Wg/ml doxycycline
(Sigma).
2.4. Western blotting
Subcon£uent HFE-HeLa-Tet-O¡ cells were lysed and 30 Wg of
soluble protein loaded on SDS-PAGE. For HFE and TfR analysis,
the samples were denatured by heating at 100‡C for 10 min in the
presence of 2% 2-mercaptoethanol, and run in 12% polyacrylamide
gels. For ferritin analysis, the samples were not heated to avoid pro-
tein disassembly and loaded on 7.5% polyacrylamide gels. After trans-
fer, the nitrocellulose ¢lters were incubated with anti-HFE antibody
(dilution 1:4000), with anti-TfR antibody (dilution 1:1000), or with
anti-H ferritin rHO2 monoclonal antibody (concentration 7 Wg/ml)
followed by secondary, peroxidase-labeled antibody (Envision,
Dako). Bound activity was revealed by ECL (Amersham).
2.5. IRP activity
Bandshift experiments for IRP activity were performed as in [22].
Cells (2U105) subjected to various treatments were lysed and 2 Wg
samples of soluble protein were incubated with a molar excess of 32P-
labeled H-ferritin IRE probe, RNase T1 and heparin in the presence
or absence of 2% 2-mercaptoethanol [22]. RNA protein complexes
were separated on 6% non-denaturing PAGE and exposed to auto-
radiography.
2.6. Cellular 55Fe incorporation
Cells (2U105) were grown for various lengths of time in the pres-
ence of 2 WCi/ml of 55Fe-NTA (0.4 WM Fe(III), 4 WM NTA) in
DMEM, 0.5% fetal calf serum, 0.5% bovine serum albumin, 150 WM
ascorbate. The cells were washed and lysed in 0.3 ml lysis bu¡er
(20 mM Tris-HCl pH 8.0, 200 mM LiCl, 1 mM EDTA, 0.5%
NP40), centrifuged and 10 Wl samples of the soluble fraction were
mixed with 0.5 ml of Ultima Gold (Packard) and counted for 3 min
in a scintillator counter (Packard). In other experiments the cells were
incubated with 0.5 WM 55Fe-transferrin for 18 h in serum-free me-
dium, and treated and counted as above.
3. Results
To study the e¡ect of HFE expression on cellular iron me-
tabolism we generated stable HeLa transfectants with the
HFE gene under the control of a tetracycline-responsive pro-
moter. The screening for HFE expression was based on im-
munoprecipitation of [35S]methionine-labeled cells with the
9E10 antibody speci¢c for the myc-tag peptide attached at
the C-terminus of the protein. From a clone grown in the
absence of doxycycline (Dox3) we immunoprecipitated a
double band of 45^47 kDa attributed to the glycosylated
and unglycosylated form of HFE, and a band of V94 kDa
corresponding to TfR. No detectable immunoprecipitate was
obtained with the same antibody when the clone was main-
tained in the presence of 2 Wg/ml doxycycline (Dox+) (not
shown). Immunocytochemistry staining with the anti-myc
antibody produced a strong, mainly intracellular decoration
in the Dox3 transfected cells and no signi¢cant background
in Dox+ cells (not shown). These ¢ndings indicated that the
HeLa clone (HFE-HeLa-Tet) expresses a myc-tagged HFE
functional in binding TfR and that the expression is fully re-
pressed by 2 Wg/ml doxycycline.
The time course of HFE accumulation after doxycycline
removal was analyzed by Western blotting. We used mouse
antisera elicited by the denatured recombinant HFE produced
in E. coli, which is speci¢c for HFE in immunoblotting and
does not cross-react with HLA molecules (not shown). The
antibody did not detect HFE in the homogenate of Dox3
cells at days 1^3 and recognized the 45^47 kDa HFE doublet
from day 7 on (Fig. 1). From densitometry of the blots in
comparison with those of known amounts of recombinant
HFE from E. coli we estimated an HFE level of about
500 ng/mg of total soluble proteins which remained constant
from day 7 to 15. Staining of the blots with an anti-TfR
antibody which recognizes denatured TfR from SDS-PAGE
[17] revealed the expected V94 kDa band in all cell homoge-
nates with an intensity that increased with the time of growth
in Dox3 to about 3^4-fold over Dox+ at day 7 (Fig. 1). An
anti-H-ferritin monoclonal antibody was used to stain blot-
tings from non-denaturing PAGE and it detected the typical
slow moving band of assembled ferritin (V500 kDa) the in-
tensity of which steadily declined in the Dox3 cells to become
virtually undetectable from day 7 on (Fig. 1). For quantitative
data, the H- and L-ferritin concentrations were evaluated with
ELISA assays based on speci¢c monoclonal antibodies and
Fig. 1. Time course of HFE expression in HeLa transfected cells.
Soluble lysates (30 Wg) of transfected cells grown in 2 Wg/ml doxycy-
cline (+) or in the absence of doxycycline for the indicated days
were subjected to SDS-PAGE, transferred to nitrocellulose and de-
tected with mouse anti-HFE antibody (1:4000), anti-transferrin re-
ceptor antibody (1:1000) or anti-H-ferritin monoclonal antibody
rHO2 (7 Wg/ml) and the appropriate peroxidase-labeled secondary
antibody (1:100). HFE and TfR were separated on 12% polyacryl-
amide gels under reducing conditions, while ferritins were separated
on 7.5% polyacrylamide gels under non-denaturing conditions. The
mobility of the 45^47 kDa bands of HFE, of the V94 kDa band
of TfR and of the ferritin bands is indicated by arrows. The ELI-
SA-derived cellular concentrations of H- and L-ferritins on the indi-
cated days of induction are shown at the bottom. MW: molecular
weight standards. Representative data from two independent experi-
ments.
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recombinant H- and L-ferritin homopolymers, they showed
an about 10-fold decrease of both H- and L-ferritin in the
Dox3 cells at day 7 (Fig. 1, bottom). The ferritin concentra-
tion of Dox+ cells (250 and 27 Wg/mg for H- and L-ferritins,
respectively) was remarkably similar to that of untransfected
parent cells (250 þ 5 and 25 þ 3 Wg/mg for H- and L-ferritins,
respectively). In addition, as a control, we analyzed a di¡erent
transfected HeLa cell clone which did not express detectable
HFE protein to ¢nd that the ferritin levels were una¡ected by
growth in the presence or the absence of 2 Wg/ml doxycycline
(not shown).
Next, we analyzed IRP activity by bandshift experiments on
cell homogenates using 32P-labeled H-ferritin IRE. In trans-
fected control HeLa cells non-expressing HFE the IRP activ-
ity was analogous in the Dox+ or Dox3 conditions (Fig. 2,
lanes 1 and 2), while in the transfected cells expressing HFE,
V2-fold higher activity was observed at day 7 in Dox3 con-
ditions (compare lanes 3 and 6 of Fig. 2). Addition of iron
salts reduced IRP activity in Dox3 and Dox+ cells, while
treatment with desferrioxamine (DFO) resulted in an evident
IRP activation in Dox+ cells, but not in Dox3 cells. The total
IRP activity detected after incubation with 2% 2-mercapto-
ethanol remained unchanged in the Dox+ and Dox3 cells.
Parallel ELISA analysis showed that FAC supplementation
increased H-ferritin levels to 470 ng/mg in Dox+ and to 440
ng/mg in Dox3 cells, while DFO treatment reduced H-ferritin
levels to 6 50 ng/mg in Dox+ and Dox3 cells.
Finally, we studied cellular iron incorporation by incubat-
ing the cells with 0.5 WM 55Fe-transferrin or with 0.4 WM
55Fe-NTA and analyzing 55Fe in the soluble extracts of the
cell homogenates. Dox3 cells, at day 7, incorporated V30%
less 55Fe-transferrin than the Dox+ cells, after 18 h incubation
(Fig. 3), while they incorporated about 30% more iron from
55Fe-NTA at 18 h incubation. It should be noted that iron
incorporation from 55Fe-NTA in the ¢rst 60 min of incuba-
tion was analogous in the Dox+ and Dox3 cells, suggesting
similar rates of iron incorporation.
4. Discussion
HFE accumulation in our HeLa transfectant clone became
evident after 7 days of growth in the absence of doxycycline,
probably the time needed to eliminate the excess of the drug
which represses the Tet promoter. The amount of accumu-
lated HFE remained constant for at least a week and was
rather high, comparable to that of the endogenous transferrin
receptor and of H-ferritin. The HFE accumulation was ac-
companied by a V3^4-fold increase of TfR levels and by a
V10-fold decrease in H- and L-ferritin levels, in agreement
with recent data [17]. IRP proteins are considered the major
sensors of cellular iron availability: their IRE binding activity
is activated by iron de¢ciency and repressed by iron availabil-
ity, although other factors such as cellular redox state and
reactive oxygen species a¡ect their functionality [23]. We ob-
served that in the conditions of maximum expression of HFE,
i.e. at day 7 of induction, IRE binding activity of IRPs was
about 2-fold higher in the HFE+ than in HFE3 cells. This
was not due to a direct e¡ect of the drug, since IRP activity in
control cells non-expressing HFE was una¡ected by doxycy-
cline (Fig. 2). Iron supplementation decreased IRP activity on
HFE+ as in HFE3 cells and increased H-ferritin content to
analogous levels. DFO treatment increased IRP activity in
HFE3, but not in the HFE+ cells in which the activity was
already high, consistent with the observation that DFO treat-
ment and HFE overexpression induced a similar decrease in
ferritin accumulation. These ¢ndings support the hypothesis
that the HFE3-induced ferritin downregulation and TfR up-
regulation are caused by an iron-mediated e¡ect on IRP ac-
tivity. Thus, HFE overexpression limits cellular iron availabil-
ity and causes an iron-de¢cient phenotype.
The upregulation of TfR in response to iron de¢ciency is
expected to increase transferrin iron uptake, while we ob-
served a signi¢cant V30% decrease, in agreement with re-
ported data [17]. This is likely caused by the physical associ-
Fig. 2. IRP activity in the induced and non-induced cells. Autora-
diograms of representative RNA bandshift assays. Lanes 1 and 2: a
transfected HeLa cell control clone non-expressing HFE was grown
for 7 days in the presence (Dox+) or the absence (Dox3) of 2 Wg/
ml doxycycline. Lanes 3^14: the HFE-HeLa-Tet clone was grown
for 7 days in the presence (Dox+) of the absence (Dox3) of 2 Wg/
ml doxycycline, as in Fig. 1; cells were untreated (lanes C), supple-
mented with 100 WM ferric ammonium citrate (lanes FAC) or 100
WM desferrioxamine for 18 h (lanes DFO). The soluble lysates (2 Wg
protein per lane) were incubated with a 32P riboprobe spanning the
IRE of the ferritin H-chain in the absence or presence of 2% 2-mer-
captoethanol (L-SH) and the RNA-protein complexes separated on
non-denaturing gel electrophoresis and exposed to autoradiography.
Representative data of three independent experiments.
Fig. 3. HFE alters transferrin-mediated and non-transferrin-medi-
ated iron incorporation after prolonged incubations. Uninduced
(Dox+, empty bars) and induced transfectant cells grown 7 days in
the absence of doxycycline (Dox3, dashed bars) were incubated for
the indicated time with 0.4 WM 55Fe-NTA (Fe:NTA 1:10 molar ra-
tio, 2 WCi/ml) or for 18 h with 0.5 WM 55Fe-transferrin. Cells were
washed, lysed and the soluble extracts counted for radioactivity and
analyzed for protein concentration. Data are means+S.D. of an ex-
periment in triplicate representative of four experiments without sig-
ni¢cant variations.
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ation of HFE with TfR which was shown to reduce TfR
capacity to bind Fe-transferrin [15^18]. The e¡ect is probably
stronger with bovine transferrin which has a lower a⁄nity for
human TfR [24], and the impaired uptake of iron from bovine
transferrin, which is the major source of iron in the medium,
should be the cause of cellular iron de¢ciency.
A novel ¢nding of this work is that HFE overexpression in
HeLa cells increases iron accumulation from non-transferrin-
bound iron (Fe-NTA) after long incubations. Previous studies
showed that Fe-NTA incorporation in HeLa cells is unaf-
fected by cellular growth rate and DFO-induced iron deple-
tion, while it is increased by pretreatment with iron salts [25].
However, cell lines with defective transferrin-mediated iron
incorporation showed higher accumulation of 59Fe-NTA
than control cells [26]. Thus, the observed higher 55Fe-NTA
incorporation in HFE+ cells is probably secondary to the
partial inactivation of TfR activity.
In conclusion, the present data demonstrate that HFE over-
expression in HeLa cells reduces cellular iron availability and
support a direct involvement of HFE in cellular iron metab-
olism. However, their physiological signi¢cance in HHC re-
mains unclear, since they suggest that the inactivation of nat-
ural HFE (e.g. in C282Y homozygous) should favor Tf-
mediated and decrease non-Tf-mediated tissue iron incorpo-
ration. However, in HHC patients and in HFE knockout mice
the Tf-mediated basolateral iron uptake in duodenal crypt
enterocytes is more likely reduced than increased [12,27],
while the non-Tf-mediated iron incorporation in absorptive
duodenal enterocytes and probably also in parenchymal cells
of the liver and other organs is increased [1,27]. Possibly the
unphysiological high overexpression of HFE in the transfec-
tant cells may produce a paradoxical e¡ect, or HFE’s role in
iron metabolism may be more complex than the only associ-
ation with TfR.
Acknowledgements: The ¢nancial support of Telethon Italy (Grant
E.649) is gratefully acknowledged. The work was partially supported
by CNR Targeted Project in Biotechnology to P.A. and A.A.
References
[1] Edwards, C.Q., Gri¡en, L.M., Goldgar, D., Drummond, C.,
Skolnick, M.H. and Kushner, J.P. (1998) New Engl. J. Med.
318, 1355^1362.
[2] Feder, J.N., Gnirke, A., Thomas, W., Tsuchihashi, Z., Ruddy,
D.A., Basava, A., Dormishian, F., Domingo, R.Jr., Ellis, M.C.,
Fullan, A., Hinton, L.M., Jones, N.L., Kimmel, B.E., Kronmal,
G.S., Lauer, P., Lee, V.K., Loeb, D.B., Mapa, F.A., McClelland,
E., Meyer, N.C., Mintier, G.A., Moeller, N., Moore, T., Mor-
ikang, E., Prass, C.E., Quintana, L., Starnes, S.M., Schatzman,
R.C., Brunke, K.J., Drayna, D.T., Risch, N.J., Bacon, B.R. and
Wol¡, R.K. (1996) Nature Genet. 13, 399^408.
[3] Jazwinska, E.C., Cullen, L., Bus¢eld, F., Pyper, W.R., Webb,
S.I., Powell, L.W., Morris, C.P. and Walsh, T.P. (1996) Nature
Genet. 14, 249^251.
[4] Jouanolle, A.M., Fergelot, P., Gandon, G., Yaouanq, J., Le Gall,
J.Y. and David, V. (1997) Hum. Genet. 100, 544^547.
[5] Carella, M., D’Ambrosio, L., Totaro, A., Grifa, A., Valentino,
M.A., Piperno, A., Girelli, D., Roetto, A., Franco, B., Gasparini,
P. and Camaschella, C. (1997) Am. J. Hum. Genet. 60, 828^832.
[6] Feder, J.N., Penny, D.M., Irrinki, A., Lee, V.K., Lebron, J.A.,
Watson, N., Tsuchihashi, Z., Sigal, E., Bjorkman, P.J. and
Schatzman, R.C. (1998) Proc. Natl. Acad. Sci. USA 95, 1472^
1477.
[7] Waheed, A., Parkkila, S., Zhou, X.Y., Tomatsu, S., Tsuchihashi,
Z., Feder, J.N., Schatzman, C., Britton, R.S., Bacon, B.R. and
Sly, W.S. (1997) Proc. Natl. Acad. Sci. USA 94, 12384^12389.
[8] Santos, M., Schilham, M.W., Rademakers, L.H., Marx, J.J., de
Sousa, M. and Clevers, H. (1996) J. Exp. Med. 184, 1975^1985.
[9] Zhou, X.Y., Tomatsu, S., Fleming, R.E., Parkkila, S., Waheed,
A., Jiang, J., Fei, Y., Brunt, E.M., Ruddy, D.A., Prass, C.E.,
Schatzman, R.C., O’Neill, R., Britton, R.S., Bacon, B.R. and
Sly, W.S. (1998) Proc. Natl. Acad. Sci. USA 95, 2492^2497.
[10] Levy, J.E., Montross, L.K., Cohen, D.E., Fleming, M.D. and
Andrews, N.C. (1999) Blood 94, 9^11.
[11] Parkkila, S., Waheed, A., Britton, R.S., Bacon, B.R., Zhou,
X.Y., Tomatsu, S., Fleming, R.E. and Sly, W.S. (1997) Proc.
Nat. Acad. Sci. USA 94, 13198^13202.
[12] Waheed, A., Parkkila, S., Saarnio, J., Fleming, R.E., Zhou, X.Y.,
Tomatsu, S., Britton, R.S., Bacon, B.R. and Sly, W.S. (1999)
Proc. Natl. Acad. Sci. USA 196, 1579^1584.
[13] Bastin, J.M., Jones, M., O’Callaghan, C.A., Schimanski, L., Ma-
son, D.Y. and Townsend, A.R. (1998) Br. J. Haematol. 103, 931^
941.
[14] Feder, J.N., Tsuchihashi, Z., Irrinki, A., Lee, V.K., Mapa, F.A.,
Morikang, E., Prass, C.E., Starnes, S.M., Wol¡, R.K., Parkkila,
S., Sly, W.S. and Schatzman, R.C. (1997) J. Biol. Chem. 272,
14025^14028.
[15] Lebron, J.A., Bennett, M.J., Vaughn, D.E., Chirino, A.J., Snow,
P.M., Mintier, G.A., Feder, J.N. and Bjorkman, P. (1998) Cell
93, 111^123.
[16] Gross, C.N., Irrinki, A., Feder, J.N. and Enns, C.A. (1998)
J. Biol. Chem. 273, 22068^22074.
[17] Roy, C.N., Penny, D.M. and Feder, J.N. (1999) J. Biol. Chem.
274, 9022^9028.
[18] Salter-Cid, S., Brunmark, A., Li, Y., Leturq, D., Peterson, P.A.,
Jackson, M.R. and Yang, Y. (1999) Proc. Natl. Acad. Sci. USA
96, 5434^5439.
[19] Corsi, B., Perrone, F., Bourgeois, R., Beaumont, C., Panzeri,
M.C., Cozzi, A., Sangregorio, R., Santambrogio, P., Albertini,
A., Arosio, P. and Levi, S. (1998) Biochem. J. 330, 315^320.
[20] Luo, W. and Lin, S.H. (1997) BioTechniques 123, 630^632.
[21] Cozzi, A., Levi, S., Bazzigaluppi, E., Ruggeri, G. and Arosio, P.
(1989) Chim. Clin. Acta 184, 197^206.
[22] Leibold, E.A. and Munro, H.N. (1988) Proc. Natl. Acad. Sci.
USA 85, 2171^2175.
[23] Hentze, M.W. and Kuhn, L.C. (1996) Proc. Natl. Acad. Sci.
USA 93, 8175^8182.
[24] Penhallow, R.C., Brown-Mason, A. and Woodworth, R.C.
(1986) J. Cell Physiol. 128, 251^260.
[25] Kaplan, J. and Jordan, I. (1991) J. Biol. Chem. 266, 2997^3004.
[26] Sturrock, A., Alexander, J., Lamb, J., Craven, C.M. and Kaplan,
J. (1990) J. Biol. Chem. 265, 3139^3145.
[27] Kuhn, L.C. (1999) Trends Biochem. Sci. 24, 164^166.
FEBS 22768 12-10-99
B. Corsi et al./FEBS Letters 460 (1999) 149^152152
